NCT04794699: Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: MTAP
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Misc Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must have progressed on at least one prior line of treatment
Exclusions: Patients with known symptomatic brain metastases that are not neurologically stable for 3 months; Patients with previous treatment of a MAT2A inhibitor and/or PRMT inhibitor

Comments are closed.

Up ↑